A Randomized, Active Therapy Controlled Phase 2 Study to Assess the Safety and Efficacy of ADXS11-001 with and without Cisplatin as 2nd Line Therapy for the Treatment of Recurrent Cervix Cancer.

Trial Profile

A Randomized, Active Therapy Controlled Phase 2 Study to Assess the Safety and Efficacy of ADXS11-001 with and without Cisplatin as 2nd Line Therapy for the Treatment of Recurrent Cervix Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Axalimogene filolisbac (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Advaxis
  • Most Recent Events

    • 12 Feb 2018 According to an Advaxis media release, data from this trial was accepted for publication in the May edition of peer-reviewed International Journal of Gynecological Cancer.
    • 12 Feb 2018 Results presented in an Advaxis media release.
    • 19 Apr 2016 Results published in Advaxis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top